Cann Global Limited's (ASX:CGB) medical Cannabis research division, Medical Cannabis Research Group Pty Ltd (MCRG) entered into a research agreement to research the possibility of the use of cannabis in the treatment of autoimmune disease, specifically multiple sclerosis (MS).
Cann Global Limited
Cann Global Limited's (ASX:CGB) primary focus is to legally grow and cultivate hemp to research and develop medicinal cannabis products to service an increasing demand in the Australian and global markets.
Cann Global Ltd has a 100% shareholding in Medical Cannabis Ltd (MCL) and a management agreement with Medcan Australia Pty Ltd (Medcan) which operate a business cultivating, researching, developing and soon to be distributing medicinal cannabis products in Australia. Our Medical Cannabis division has been a key value driver for the Group.
The Group also retains an interest in its existing Bauxite Projects.
The Board of Cann Global Limited (ASX:CGB) wishes to update our shareholders on the operations of its 55% owned subsidiary Cann Global Asia Pty Ltd, and its activities in Laos PDR.
On 30 April 2020, Cann Global Ltd (ASX:CGB) lodged the Company's quarterly activities and cashflow reports for the period ended 31 March 2020. This amendment includes an updated cashflow report.
In October 2019, Austrade published a report on Australia's food innovators which Cann Global Limited (ASX:CGB), through its subsidiaries T12 and HHC, is very excited to be a part of.
Cann Global Ltd (ASX:CGB) is pleased to advise that the Company has entered into agreements for the refinancing of the convertible notes currently on issue through an assignment and variation arrangement.
The Directors present their report together with the financial statements, on the consolidated entity (referred to hereafter as 'the Group'), consisting of Cann Global Limited ('the Company') and the entities it controlled at the end of or during the half-year ended 31 December 2019.
Cann Global Ltd (ASX:CGB) is pleased to advise that the Company has agreed to place 34 million new fully paid ordinary shares (New Shares) to institutional and sophisticated investors led by New York-based Sea Otter Global.
Cann Global Limited (ASX:CGB) was pleased to announce a distribution agreement with Costco Australia for our premium quality certified organic hemp seed oil capsules in September.
The Board of Cann Global Limited (ASX:CGB) is pleased to provide an update on its recent exclusive distributorship supply contract deal signed with EPCO Foods Co. Ltd in Ho Chi Minh City, Vietnam and its supply of T12 products to COSTCO Australia.
The Board of Cann Global Limited (ASX:CGB) is pleased to announce that it has entered into a Heads of Agreement with the South African company Koegas Medicinal Herbs (Pty) Ltd to establish a Joint Venture (CGB to hold 70%) in medicinal Cannabis production and distribution in Africa.